Use of Uceris (budesonide) rectal foam with oral prednisone
Uceris (budesonide) rectal foam contains a glucocorticosteroid. [1]
Using oral prednisone at the same time increases total corticosteroid exposure. [1]
Concomitant use is not specifically prohibited in the prescribing information, but monitoring and prescriber oversight are required because systemic steroid effects can occur (including adrenal suppression and infection risk). [1]
Clinical guidance on combining steroid therapies
For mild-to-moderate ulcerative colitis, rectal corticosteroids and systemic corticosteroids are typically used as treatment options based on extent and response to prior therapy rather than as an explicitly recommended routine combination. [2]
AGA guidance supports using either oral prednisone (or budesonide MMX) as systemic steroid therapy when needed for patients with disease refractory to optimized topical and oral 5-ASA. [2]
Medication safety considerations
UCERIS rectal foam can contribute to hypercorticism and adrenal suppression. [1]
Transferring from higher-systemic corticosteroids to UCERIS rectal foam requires monitoring because adrenal suppression or withdrawal-related symptoms may occur. [1]
When systemic corticosteroids are used concurrently, additive risk of glucocorticoid adverse effects is expected. [1]
UCERIS rectal foam also increases infection risk in the setting of immune suppression. [1]
Practical decision points for whether to take both
Taking both together should be done only under the prescribing clinician’s direction due to additive systemic corticosteroid exposure and associated risks. [1]
Dose changes or a switch from one corticosteroid regimen to another should be coordinated because adrenal suppression can occur and tapering may be necessary. [1]
If worsening symptoms, significant side effects, or signs of infection occur, urgent clinician contact is indicated due to the immunosuppression risk with corticosteroids. [1]
Common steroid-related warning signs requiring urgent medical contact
Medical attention should be sought for symptoms of adrenal suppression, including marked fatigue, weakness, nausea, vomiting, or low blood pressure. [1]
Medical attention should be sought for symptoms of infection because risk is increased with glucocorticosteroid therapy. [1]
Key interaction considerations
No direct drug-drug interaction between UCERIS rectal foam and oral prednisone is highlighted in the prescribing information. [1]
CYP3A4 inhibitors are a key interaction class for UCERIS rectal foam because they can increase systemic budesonide concentrations. [1]
When “together” is most likely intended
Concurrent steroid therapy is most commonly intended when clinicians are escalating induction therapy for an active flare rather than using UCERIS foam as the sole steroid regimen. [2]
This plan should be confirmed with the prescriber because the safest regimen depends on disease extent, prior response, and the intended corticosteroid strategy. [2]